Clinical Trial Update: Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy [Phase 2]

View source ↗

Summary

Phase II randomized, multicenter, open-label study evaluating Lucentis monotherapy versus Lucentis plus panretinal photocoagulation (PRP) and PRP alone in high-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: José Cunha-Vaz | Conditions: High Risk Proliferative Diabetic Retinopathy | Phase 2 | Status: COMPLETED